These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 26356564)
1. Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome. Rea K; Pinciroli P; Sensi M; Alciato F; Bisaro B; Lozneanu L; Raspagliesi F; Centritto F; Cabodi S; Defilippi P; Avanzi GC; Canevari S; Tomassetti A Oncotarget; 2015 Oct; 6(31):30859-75. PubMed ID: 26356564 [TBL] [Abstract][Full Text] [Related]
2. Computational and Immunohistochemical Analyses Highlight AXL as a Potential Prognostic Marker for Ovarian Cancer Patients. Lozneanu L; Pinciroli P; Ciobanu DA; Carcangiu ML; Canevari S; Tomassetti A; Căruntu ID Anticancer Res; 2016 Aug; 36(8):4155-63. PubMed ID: 27466525 [TBL] [Abstract][Full Text] [Related]
3. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures. Ow GS; Ivshina AV; Fuentes G; Kuznetsov VA Cell Cycle; 2014; 13(14):2262-80. PubMed ID: 24879340 [TBL] [Abstract][Full Text] [Related]
4. AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Rankin EB; Fuh KC; Taylor TE; Krieg AJ; Musser M; Yuan J; Wei K; Kuo CJ; Longacre TA; Giaccia AJ Cancer Res; 2010 Oct; 70(19):7570-9. PubMed ID: 20858715 [TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells. Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942 [TBL] [Abstract][Full Text] [Related]
6. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030 [TBL] [Abstract][Full Text] [Related]
7. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival. Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455 [TBL] [Abstract][Full Text] [Related]
8. Axl is a prognostic marker in oral squamous cell carcinoma. Lee CH; Yen CY; Liu SY; Chen CK; Chiang CF; Shiah SG; Chen PH; Shieh YS Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S500-8. PubMed ID: 21842265 [TBL] [Abstract][Full Text] [Related]
9. Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients. Ishikawa M; Sonobe M; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Date H Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S467-76. PubMed ID: 23242819 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies. Kariolis MS; Miao YR; Diep A; Nash SE; Olcina MM; Jiang D; Jones DS; Kapur S; Mathews II; Koong AC; Rankin EB; Cochran JR; Giaccia AJ J Clin Invest; 2017 Jan; 127(1):183-198. PubMed ID: 27893463 [TBL] [Abstract][Full Text] [Related]
11. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer. Mishra A; Wang J; Shiozawa Y; McGee S; Kim J; Jung Y; Joseph J; Berry JE; Havens A; Pienta KJ; Taichman RS Mol Cancer Res; 2012 Jun; 10(6):703-12. PubMed ID: 22516347 [TBL] [Abstract][Full Text] [Related]
12. Gas6 expression and Tyrosine kinase Axl Sky receptors: Their relation with tumor stage and grade in patients with bladder cancer. Akgül M; Baykan Ö; Çağman Z; Özyürek M; Tinay İ; Akbal C; Uras F; Türkeri L Arch Ital Urol Androl; 2021 Jun; 93(2):148-152. PubMed ID: 34286546 [TBL] [Abstract][Full Text] [Related]
13. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Zhu C; Wei Y; Wei X Mol Cancer; 2019 Nov; 18(1):153. PubMed ID: 31684958 [TBL] [Abstract][Full Text] [Related]
14. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target. Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560 [TBL] [Abstract][Full Text] [Related]
15. AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier. Seike M; Kim CH; Zou F; Noro R; Chiba M; Ishikawa A; Κunugi S; Kubota K; Gemma A Oncol Rep; 2017 Jun; 37(6):3261-3269. PubMed ID: 28440492 [TBL] [Abstract][Full Text] [Related]
16. Relationship Between Increased Expression of the Axl/Gas6 Signal Cascade and Prognosis of Patients with Upper Tract Urothelial Carcinoma. Hattori S; Kikuchi E; Kosaka T; Miyazaki Y; Tanaka N; Miyajima A; Mikami S; Oya M Ann Surg Oncol; 2016 Feb; 23(2):663-70. PubMed ID: 26350366 [TBL] [Abstract][Full Text] [Related]
17. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Rankin EB; Fuh KC; Castellini L; Viswanathan K; Finger EC; Diep AN; LaGory EL; Kariolis MS; Chan A; Lindgren D; Axelson H; Miao YR; Krieg AJ; Giaccia AJ Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13373-8. PubMed ID: 25187556 [TBL] [Abstract][Full Text] [Related]
18. Tumor-associated macrophages promote oral cancer progression through activation of the Axl signaling pathway. Lee CH; Liu SY; Chou KC; Yeh CT; Shiah SG; Huang RY; Cheng JC; Yen CY; Shieh YS Ann Surg Oncol; 2014 Mar; 21(3):1031-7. PubMed ID: 24276640 [TBL] [Abstract][Full Text] [Related]
19. Glycoxidised LDL induced the upregulation of Axl receptor tyrosine kinase and its ligand in mouse mesangial cells. Kim YS; Jung DH; Sohn E; Kim J; Kim JS PLoS One; 2012; 7(11):e50297. PubMed ID: 23226259 [TBL] [Abstract][Full Text] [Related]
20. Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy. Kanzaki R; Naito H; Kise K; Takara K; Eino D; Minami M; Shintani Y; Funaki S; Kawamura T; Kimura T; Okumura M; Takakura N Sci Rep; 2017 Sep; 7(1):10613. PubMed ID: 28878389 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]